NCT00274248View on ClinicalTrials.gov

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2007

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

MLN518

Trial Locations (1)

02134

The Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY